<DOC>
	<DOCNO>NCT00898807</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy citalopram agitation Alzheimer 's dementia .</brief_summary>
	<brief_title>Citalopram Agitation Alzheimer 's Disease</brief_title>
	<detailed_description>This study design examine efficacy safety citalopram treatment clinically significant agitation Alzheimer 's dementia ( AD ) patient . It also investigate pharmacogenomic , genetic , clinical predictor response citalopram therapy . The management agitation major priority treat patient AD . Non-pharmacologic option limit effectiveness . Several pharmacologic option explore , finding anticonvulsant , antipsychotic , cholinesterase inhibitor disappoint associate questionable risk-benefit ratio . Better pharmacologic option need . Selective serotonin reuptake inhibitor ( SSRIs ) show promise treatment agitation AD , base evidence link agitation brain serotonin system abnormality AD patient , preliminary clinical data single-site , randomize control trial ( RCT ) citalopram superior perphenazine placebo .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Inclusion criterion Probable Alzheimer 's disease ( National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association criterion ) , MiniMental score 528 inclusive A medication agitation appropriate , opinion study physician Clinically significant agitation either 1. frequency agitation assess Neuropsychiatric Inventory ( NPI ) 'Very frequently ' , 2. frequency agitation assess NPI 'Frequently ' AND severity agitation assess NPI 'Moderate ' , 'Marked ' Provision inform consent participation study patient surrogate ( necessary ) caregiver Availability primary caregiver , spend several hour week patient supervise his/her care , accompany patient study visit participate study No change Alzheimer 's disease ( AD ) medication within month precede randomization , include start , stop , dosage modification Exclusion criterion Meets criteria Major Depressive Episode Diagnostic Statistical Manual Mental Disorders , 4th edition , text revision ( DSMIV ( TR ) ) criterion Presence brain disease might otherwise explain presence dementia , extensive brain vascular disease , Parkinson 's disease , dementia Lewy body , traumatic brain injury , multiple sclerosis Psychosis ( delusion hallucination ) require antipsychotic treatment opinion study physician Prolonged measure time start Q wave end T wave heart 's electrical cycle ( QT interval ) Treatment citalopram contraindicate opinion study physician Failure past treatment citalopram agitation adequate trial minimally accept dose ( great equal 20 mg/day ) Treatment medication would prohibit safe concurrent use citalopram , Monoamine oxidases ( MAO ) inhibitor Need psychiatric hospitalization suicidal Current participation clinical trial study may add significant burden affect neuropsychological study outcome Current treatment antipsychotic , anticonvulsant ( dilantin ) , antidepressant ( trazodone , less equal 50 mg per day bedtime ) , benzodiazepine ( lorazepam ) , psychostimulants Any condition , opinion study physician , make medically inappropriate risky patient enroll trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>neuropsychiatric symptom</keyword>
	<keyword>aggression</keyword>
	<keyword>mood lability</keyword>
</DOC>